GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (lse/nyse:GSK) and Theravance, Inc. THRX +1.96% today announced that Anoro™ Ellipta® ...

GlaxoSmithKline and Innovia announced new data at the American Thoracic Society (ATS) 2016 International Conference regarding the safety and efficacy of Anoro Ellipta ...

Anoro Ellipta should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy for the treatment of acute episodes of ...

Anoro should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD, or as rescue therapy for the treatment of acute episodes of bronchospasm, which ...

Anoro Ellipta is meant to be used as a long-term treatment for COPD. If you and your doctor determine that Anoro is safe and effective for you, you’ll likely take it long term.

Anoro gained unanimous approval on efficacy. That's not surprising. Theravance and Glaxo announced very positive results in July 2012 from four phase 3 studies of the drug. Anoro was found to be more ...

The FINANCIAL — GlaxoSmithKline plc (GSK) and Theravance, Inc. on September 27 announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001), from an ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

An FDA panel gives a big thumbs-up for Theravance's Anoro Ellipta. Trading of biopharmaceutical company Theravance (NASDAQ: THRX) was halted on Tuesday. A major decision hung in the balance as the U.S ...